MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14712598.2023.2215923

Медицинская библиотека · Expert opinion on biological therapy · 2023

Anti-IL17 treatment in childhood chronic rheumatic diseases.

Maniscalco Valerio, Maccora Ilaria, Girodo Flavio, Tomaselli Marta, Priolo Gaia, Marrani Edoardo, Mastrolia Maria Vincenza, Pagnini Ilaria, Simonini Gabriele

СтатьяОбзорПеревод в очереди

Аннотация

INTRODUCTION

Interleukin-17 (IL-17) is a family of cytokines that plays a key role in several rheumatic diseases in both adults and children. In the last few years, several drugs targeting IL-17 have been developed.

AREAS COVERED: We present a review on the current state of the art regarding the use of anti-IL17 in childhood chronic rheumatic diseases. To date, the available evidence is limited and mainly focuses on juvenile idiopathic arthritis (JIA) and a specific autoinflammatory disease called deficiency of IL-36 receptor antagonist (DITRA). Recently, a randomized controlled trial resulted in the approval of secukinumab (an anti-IL17 monoclonal antibody) for JIA, due to its demonstrated efficacy and safety. Promising and potential uses of anti-IL17 in Behçet's syndrome and synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome have also been described.

EXPERT OPINION: Increasing knowledge about the pathogenetic mechanisms underlying rheumatic diseases is leading to an improvement in the care of several chronic autoimmune diseases. In this scenario, anti-IL17 therapies (such as secukinumab and ixekizumab) might be an optimal choice. Recent data on the use of secukinumab in juvenile spondyloarthropathies can be a starting point for future treatment strategies in other pediatric rheumatic diseases, such as Behçet's syndrome and the chronic non-bacterial osteomyelitis disease spectrum, particularly SAPHO syndrome.

Для цитирования: Maniscalco Valerio, Maccora Ilaria, Girodo Flavio, Tomaselli Marta, Priolo Gaia, Marrani Edoardo, Mastrolia Maria Vincenza, Pagnini Ilaria, Simonini Gabriele. Anti-IL17 treatment in childhood chronic rheumatic diseases.. Expert opinion on biological therapy. 2023. DOI: 10.1080/14712598.2023.2215923.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.